A team of researchers at Texas Children’s Duncan Neurological Research Institute (NRI) and Baylor College of Medicine report in Science Translational Medicine a potential new approach to treat Rett ...

A new gene-targeting strategy that boosts a crucial brain protein could pave the way for the first effective treatment for Rett syndrome. Researchers at Texas Children’s Duncan Neurological Research I ...

A team of researchers at Texas Children's Duncan Neurological Research Institute (NRI) and Baylor College of Medicine ...

A team of researchers at Baylor College of Medicine and the Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital reports ...

Careful assessment of symptom patterns allows treatment strategies to be aligned with the patient’s specific challenges ...

Gene therapy that can cross the blood–brain barrier represents a non-invasive way to map gene expression in the brains of ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AßOs) for the treatment of Alzheimer ...

Potassium KCNQ2/3 channels are crucial for suppressing the excitability of brain cells, or neurons. When these channels don't work properly, they can cause specific types of epilepsy like benign ...

Microbiology research responds to medical student's critique of unproven alternative treatments. One-size-fits-all medical guidelines are not based on the full spectrum of evidence.

Experts call for early diagnosis, prophylaxis in hemophilia, improved MS policy frameworks, genomic testing access and ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, recognizes ...

Platform to detect human-relevant insights for discovery and development of therapies for neurological diseases, ...